Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer-Reference-Cited by-全球学者库

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

Published:2021-03 Issue:3 Volume:32 Page:395-403
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Perets R.,Bar J.,Rasco D.W.,Ahn M.-J.,Yoh K.,Kim D.-W.,Nagrial A.,Satouchi M.,Lee D.H.,Spigel D.R.,Kotasek D.,Gutierrez M.,Niu J.,Siddiqi S.,Li X.,Cyrus J.,Chackerian A.,Chain A.,Altura R.A.,Cho B.C.

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference26 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

2. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int Immunopharmacol,2018

3. Tumor immunotherapy directed at PD-1;Ribas;N Engl J Med,2012

4. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade;Wei;Cell,2017

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments;World Journal of Surgical Oncology;2024-01-23

2. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

3. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome;Therapeutic Advances in Medical Oncology;2024-01

4. Cancer CD39 drives metabolic adaption and mal-differentiation of CD4+ T cells in patients with non-small-cell lung cancer;Cell Death & Disease;2023-12-08

5. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma;Future Oncology;2023-12